Comparative Pharmacology
Head-to-head clinical analysis: TRI LO SPRINTEC versus TRI LINYAH.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TRI LO SPRINTEC versus TRI LINYAH.
TRI LO SPRINTEC vs TRI-LINYAH
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Tri-Lo Sprintec is a combination oral contraceptive containing ethinyl estradiol and norgestimate. It inhibits ovulation by suppressing gonadotropin release (FSH and LH) from the pituitary, increases viscosity of cervical mucus, and alters endometrial receptivity.
Combination hormonal contraceptive: ethinyl estradiol and norgestimate. Suppresses gonadotropin release, inhibiting ovulation; also increases cervical mucus viscosity and alters endometrial morphology.
Prevention of pregnancy
Prevention of pregnancyTreatment of moderate acne vulgaris in women aged ≥15 years who have achieved menarche and are using oral contraception (off-label)
One tablet (0.035 mg ethinyl estradiol + 0.180/0.215/0.250 mg norgestimate) orally once daily for 28-day cycle: active tablets on days 1-21, placebo on days 22-28.
One tablet orally once daily for 21 days, followed by 7 placebo tablets. Each tablet contains 0.035 mg ethinyl estradiol and 0.180/0.215/0.250 mg norgestimate.
None Documented
None Documented
Ethinyl estradiol: terminal half-life approximately 17 hours. Norelgestromin (active metabolite of norgestimate): terminal half-life approximately 28 hours. Clinical context: Ethinyl estradiol half-life supports once-daily dosing with steady-state reached within 7-14 days; norelgestromin half-life allows for sustained progestogenic effect.
Ethinyl estradiol: terminal half-life approximately 17 hours (range 13–27 hours), supporting once-daily dosing; norgestimate's active metabolite norelgestromin: terminal half-life approximately 28 hours.
Ethinyl estradiol is metabolized primarily via CYP3A4; norgestimate is rapidly metabolized to norelgestromin and subsequently to norgestrel, with further metabolism involving CYP3A4 and other CYP enzymes.
Ethinyl estradiol: primarily metabolized by CYP3A4, undergoes hydroxylation and conjugation. Norgestimate: rapidly hydrolyzed to norelgestromin and further metabolized by CYP3A4, CYP2C9, and CYP2C19.
Renal (approximately 50-60% as metabolites, with about 20% as unchanged ethinyl estradiol glucuronide and 40% as norgestimate metabolites). Fecal (approximately 30-40% as metabolites).
Ethinyl estradiol is excreted in urine (40%) and feces (60%) as glucuronide and sulfate conjugates; norgestimate is primarily eliminated via renal excretion (46%) and fecal excretion (47%) as metabolites.
Ethinyl estradiol: approximately 97-98% bound to albumin, 2% free. Norelgestromin: approximately 99% bound to sex hormone-binding globulin (SHBG) and albumin.
Ethinyl estradiol: ~97% bound to serum albumin; norelgestromin: ~99% bound, primarily to albumin and sex hormone-binding globulin (SHBG).
Ethinyl estradiol: Vd approximately 4-5 L/kg. Norelgestromin: Vd approximately 3-4 L/kg. Clinical meaning: indicates extensive distribution into tissues, not primarily confined to plasma volume.
Ethinyl estradiol: Vd approximately 2–4 L/kg, indicating extensive tissue distribution; norelgestromin: Vd approximately 2.7 L/kg.
Oral: ethinyl estradiol bioavailability approximately 45% (first-pass effect); norgestimate prodrug converted to norelgestromin with systemic bioavailability of approximately 63%.
Oral bioavailability of ethinyl estradiol: ~55% (with interindividual variability); norgestimate: rapidly and extensively converted to active norelgestromin; absolute bioavailability not reported due to extensive first-pass metabolism.
No specific dosing adjustment required for renal impairment. Use caution in severe renal impairment due to potential fluid retention.
No dose adjustment required for mild to moderate renal impairment. Contraindicated in severe renal disease or acute renal failure.
Contraindicated in severe hepatic disease or hepatocellular carcinoma. For mild to moderate hepatic impairment (Child-Pugh A or B), use alternative contraception; no established dosing guidelines.
Contraindicated in acute hepatic disease or severe hepatic impairment. For Child-Pugh Class B or C, contraindicated. No data for mild impairment.
Not indicated for use before menarche. Post-menarche: same dosing as adults (one tablet daily). Safety and efficacy established in females of reproductive age.
Not indicated for females with menarche before age 18. Use same dosing as adults post-menarche.
Not indicated for postmenopausal women; no geriatric dosing established.
Not indicated for postmenopausal women. No specific dose adjustments for elderly, but consider increased risk of thromboembolism, cardiovascular disease, and contraindication in women >35 years who smoke 15+ cigarettes daily.
Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive use. This risk increases with age and with heavy smoking (≥15 cigarettes per day) and is quite marked in women over 35 years of age. Women who use combination oral contraceptives should be strongly advised not to smoke.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptives. Risk increases with age (especially >35 years) and with number of cigarettes smoked. Women who use oral contraceptives should be strongly advised not to smoke.
["Increased risk of thromboembolic disorders (e.g., venous thromboembolism, stroke, myocardial infarction)","Cigarette smoking increases risk of serious cardiovascular events","Increased risk of hepatic neoplasia (benign and malignant)","Elevated blood pressure","Gallbladder disease","Carbohydrate and lipid metabolic effects"]
Thrombotic disorders (venous and arterial), cigarette smoking, elevated blood pressure, gallbladder disease, carbohydrate/lipid effects, headache, hepatic neoplasia, ocular disturbances, interactions with other drugs.
["Known or suspected pregnancy","Current or history of thrombophlebitis or thromboembolic disorders","Cerebrovascular or coronary artery disease","Known or suspected breast cancer or other estrogen-sensitive neoplasia","Undiagnosed abnormal uterine bleeding","Benign or malignant liver tumor or active liver disease","Hypersensitivity to any component","Use of hepatitis C drug combinations containing ombitasvir/paritaprevir/ritonavir with or without dasabuvir"]
Thrombophlebitis or thromboembolic disorders, cerebral vascular/coronary artery disease, known or suspected pregnancy, undiagnosed abnormal genital bleeding, known or suspected breast cancer, hepatic tumor or active liver disease, hypersensitivity to any component, current or past history of migraine with focal neurological symptoms (if age ≥35), diabetes with vascular involvement, uncontrolled hypertension, cigarette smoking in women >35
Data Pending Review
Data Pending Review
No significant food interactions. Grapefruit may slightly alter estrogen metabolism but clinically not significant. Maintain consistent dietary habits if constipating.
No specific food restrictions. Grapefruit juice may have a minor interaction but is not considered clinically significant. Alcohol does not directly affect efficacy, but excessive consumption may impair judgment or increase risk of liver issues.
FDA Category X. Use contraindicated in pregnancy due to risk of congenital anomalies, particularly cardiovascular and limb defects, from exposure during first trimester. Second and third trimester exposure associated with potential for fetal harm, including androgenization of female fetuses and liver adenoma. Discontinue promptly if pregnancy occurs.
TRI-LINYAH (levonorgestrel/ethinyl estradiol) is contraindicated in pregnancy. First trimester: no increased risk of major birth defects from inadvertent use, but intended use contraindicated. Second and third trimesters: known risks including feminization of male fetuses, cardiovascular and neurologic effects from progestin exposure, and estrogenic effects on fetal development.
Enters breast milk in small amounts (M/P ratio not established). May reduce milk production and quality. Use caution in nursing mothers, especially during early postpartum period. Consider alternative contraception until weaning.
Excreted in breast milk; M/P ratio for ethinyl estradiol is approximately 0.2-0.5, for levonorgestrel 0.1-0.3. May reduce milk production and quality; use only if benefits outweigh risks, preferably after weaning.
Contraindicated in pregnancy; no dose adjustments recommended as use is precluded. If inadvertently used, discontinue immediately.
Contraindicated during pregnancy; no dose adjustments applicable. If exposure occurs, discontinue immediately.
Category C
Category C
Tri-Lo Sprintec is a triphasic oral contraceptive with ethinyl estradiol and norgestimate. Monitor for thromboembolic events, especially in smokers over 35. Advise use of backup contraception if vomiting/diarrhea occurs. CYP3A4 inducers may reduce efficacy.
Tri-Linyah is a combination oral contraceptive containing ethinyl estradiol and norgestimate. It follows a 28-day cycle with 21 active pills and 7 placebo pills. The risk of venous thromboembolism is increased, especially in smokers over 35. Efficacy may be reduced with CYP3A4 inducers such as rifampin or certain anticonvulsants. Missed doses require specific instructions: if one active pill is missed, take as soon as remembered; if two are missed, take two pills daily for two days and use backup contraception. Breakthrough bleeding is common in the first few cycles. Use with caution in patients with migraine with aura, hypertension, or history of cholestatic jaundice.
Take one tablet daily at the same time; missed doses increase pregnancy risk.Use backup contraception for 7 days after missing 2 or more pills.Report symptoms of blood clots: leg pain/swelling, chest pain, sudden shortness of breath.Avoid smoking while on this medication, especially if over 35.May cause irregular bleeding initially; contact provider if persistent.
Take one pill daily at the same time each day, with or without food.If you miss a pill, follow the package insert instructions: for missed active pills, take as soon as remembered and use backup contraception if necessary.Smoking increases the risk of serious cardiovascular side effects, especially if you are over 35 years old. Do not smoke while taking this medication.Contact your healthcare provider if you experience severe headaches, chest pain, leg pain or swelling, vision changes, or jaundice.Antibiotics (except rifampin) generally do not affect efficacy, but always inform your doctor of all medications you are taking.Store at room temperature away from moisture and heat.